Cardiovascular

Latest News
May 6th 2025

Effect of Remote Patient Monitoring on Stage 2 Hypertension

April 24th 2025

Abelacimab Demonstrates Safety and Efficacy for Patients With AFib of All Ages: Sid Patel, MD

April 18th 2025

"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health

April 8th 2025

Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD

April 4th 2025

High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment

Lipoprotein(a) and Cardiovascular Risk

Learn about more about lipoprotein(a), including how to improve patient outcomes through better screening and management.

AJMC Peer Exchange logo
Video Interviews
View All
May 6th 2025

Technological Advances in CV Care Depend on Human Resources: Antoine Keller, MD

May 5th 2025

Lp(a) Testing: Prevalence and Strategies to Improve Uptake

May 5th 2025

Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment

April 28th 2025

The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies

April 28th 2025

FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels

April 21st 2025

Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing

April 21st 2025

Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing

April 14th 2025

Evidence Supporting 2024 Guidance for Lp(a) Testing

April 14th 2025

The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

April 10th 2025

Lp(a) Awareness Imperative for Enhancing Testing, Prevention Efforts in CVD: Joseph Saseen, PharmD

Podcasts
View All
May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

May 10th 2022

For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management

February 22nd 2020

Podcast: This Week in Managed Care—Setbacks for Medicaid Work Rules and Other Health News

June 2nd 2019

Podcast: This Week in Managed Care—The $2 Million Gene Therapy and Other Health News

December 1st 2018

Podcast: This Week in Managed Care—CMS Drug Coverage Changes Draw Ire and Other Health News

November 18th 2018

Podcast: This Week in Managed Care—Cancer Is the New Leading Cause of Death and Other Health News

November 10th 2018

Podcast: This Week in Managed Care—Medicaid Expansion at the Ballot Box and Other Health News

June 17th 2017

Podcast: This Week in Managed Care - Dropped ACA Coverage, and Other News

Continuing Medical Education
View All
May 7th 2025

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases
May 7th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
May 7th 2025

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

1.0 Credit / Cardiology

More News

A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk
April 7th 2025

A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss an example illustrating the association between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD) risk and explore how this example can inform our understanding of Lp(a) and ASCVD risk on a population level.
How the Genetic Nature of Lp(a) Levels Influences Screening
April 7th 2025

How the Genetic Nature of Lp(a) Levels Influences Screening

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss the genetic determinants of lipoprotein(a) (Lp[a]) levels, providing evidence supporting this conclusion. They also explore how the hereditary nature of Lp(a) can drive awareness of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis risk, potentially influencing screening protocols.
Heart disease is, and has been, the number 1 cause of death for Americans over the last century | image credit: Thirakun - stock.adobe.com
April 2nd 2025

Digital Solutions Can Transform CVD Care, Prevention

Kyle Munz
Mobile self-management programs like that offered by Hello Heart can benefit employers and patients alike as they seek to manage and prevent heart disease.
Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime
March 31st 2025

Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss the evidence supporting the continuous relationship between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD), as recognized by the National Lipid Association, and explore how Lp(a) levels may change throughout a person’s lifetime or in response to lifestyle factors.
Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease
March 31st 2025

Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss the relationship between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD) risk, with findings from a large US population study, and explore how these findings could impact clinical practice and the management of patients at risk for ASCVD.
Jaime Murillo, MD
March 29th 2025

AI Is Changing the Landscape of Cardiovascular Care

Kyle Munz Jaime Murillo, MD
Implementing artificial intelligence (AI) has transformed clinicians' and health systems' ability to screen for and distinguish forms of cardiorenalmetabolic disease.
Improving Cardiovascular Treatment Adherence Through Education, Engagement
March 26th 2025

Improving Cardiovascular Treatment Adherence Through Education, Engagement

Kyle Munz Jaime Murillo, MD
Jaime Murillo, MD, discusses the importance of fostering open communication with patients as a means of encouraging adherence to various treatments.
Nathan Wong, PhD
March 24th 2025

Raising Awareness of Lp(a) to Improve Heart Disease Treatment Approaches

Kyle Munz Nathan Wong, PhD
Lipoprotein(a) [Lp(a)] plays a key role in assessing cardiovascular risk, making awareness efforts equally essential for prevention and early intervention.
The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis
March 24th 2025

The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss the clinical and economic burden of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis in the US, exploring their impact on health care systems, the importance of prevention in reducing this burden, and the challenges of implementing preventive strategies, while considering the potential benefits of improved risk assessment and prevention in the ASCVD space.
Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis
March 24th 2025

Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss atherosclerotic cardiovascular disease and aortic stenosis, as well as their burden, highlighting their prevalence, impact on patient health, and the growing need for effective management strategies.
FDA Approval | image credit: PKartstudio - stock.adobe.com
March 21st 2025

FDA Approves Vutrisiran to Mitigate Cardiomyopathy-Related Risks and Conditions

Kyle Munz
In a recent decision, the FDA approved vutrisiran (amvuttra), making it the only approved therapy for adults with hereditary transthyretin-mediated amyloidosis (ATTR-CM) or wild-type cardiomyopathy.
Nihar Desai, MD, MPH
March 20th 2025

PROMPT Trials, Electronic Alerts, and Enhancing CV Outcomes

Kyle Munz Nihar Desai, MD, MPH
The PROMPT trials evaluate the influence of electronic health alerts for informing appropriate, evidence-based therapies to patients with cardiovascular conditions.
Tom Belmont
March 17th 2025

2025 GPBCH Employer Symposia Set to Address Cardiovascular, MSK Challenges

Kyle Munz Tom Belmont
Tom Belmont, president and CEO, Greater Philadelphia Business Coalition on Health (GPBCH) previews the upcoming employer symposia, which seeks to help employers navigate solutions for the management and prevention of cardiovascular and musculoskeletal disease.
Semaglutide. | Image Credit: K KStock - stock.adobe.com
March 14th 2025

Tirzepatide and Semaglutide Improve Weight Loss, Cardiovascular Conditions, but Deemed Too Expensive

Cameron Santoro
Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they are not cost-effective at their current prices, according to a new evaluation, placing economic burdens on patients with obesity in the US.
Dallas Texas | Image Credit: © SeanPavonePhoto - stock.adobe.com
March 13th 2025

Value-Based Care Is Key to Bringing Cardiology Breakthroughs to Those Who Will Benefit Most

Christina Mattina
On December 10, 2024, cardiologists, researchers, and value-based care experts gathered in Dallas, Texas, to discuss best practices for implementing advances in cardiology care with a value-based mindset, spanning the care continuum from prevention to treatment.
Pittsburgh, Pennsylvania | Image Credit: © SeanPavonePhoto - stock.adobe.com
March 13th 2025

Reducing Care Fragmentation to Boost CKM Disease Outcomes

Maggie L. Shaw
Discussions at a recent Institute for Value-Based Medicine® event highlighted the interconnected nature of cardio-kidney-metabolic disease and emphasized the need for integrated, patient-centered care.
Phoenix Arizona | Image Credit: © Kevin Ruck - stock.adobe.com
March 12th 2025

Closing the Gaps in Cardiac Care With Technology, Collaboration

Christina Mattina
Cardiologists, primary care physicians, and value-based care leaders convened in Phoenix, Arizona, on November 12, 2024, to share case studies and insights on how to align cardiology with the principles of value-based care, including through the application of digital tools.
Antoine Keller, MD
March 12th 2025

Leveraging AI, Digital Auscultation to Streamline Cardiovascular Diagnoses

Kyle Munz Antoine Keller, MD, FACC, FACS
Advancing technologies have transformed the detection of heart disease and, in turn, streamlined medical processes and relieved burden on health care systems.
AJMC
March 6th 2025

Clinical Outcomes in Heart Failure Monitoring: A Pooled Rates Analysis

Ubong Silas, MSc Juliane Hafermann, PhD Antonia Bosworth Smith, MSc Alex Veloz, MSc Rhodri Saunders, PhD D. Eric Steidley, MD
This systematic literature review and pooled rates analysis investigated the standard of care for patients with heart failure in the US post hospital discharge.
Guidelines-momius-stock.adobe.com
February 28th 2025

AHA, ACC Update Guidelines for Acute Coronary Syndrome Management

Giuliana Grossi
The 2025 guideline introduces notable updates including refined recommendations for dual antiplatelet therapy, cardiogenic shock management, and secondary prevention.
Aortic Stenosis remains a serious, worldwide cardiovascular complication | image credit: Pumpala - stock.adobe.come
February 19th 2025

Cardiovascular Magnetic Resonance Highlights Sex-Specific Characteristics in Aortic Stenosis

Kyle Munz
This multicenter study sheds more light on sex-based differences in aortic stenosis (AS) and argues the benefits of using cardiovascular magnetic resonance (CMR) to assess sex-based risks in AS.
Antoine Keller, MD
February 18th 2025

HeartSense's Mission to Reveal, Combat Hidden CV Burdens in Underserved Communities

Kyle Munz Antoine Keller, MD, FACC, FACS
Antoine Keller, MD, founded HeartSense with the purpose of uncovering and addressing the cardiovascular needs of rural, often underserved communities.
Heart health. | Image Credit: udra11 - stock.adobe.com
February 14th 2025

5 Things That Impact Heart Health

Cameron Santoro
To maintain a healthy heart, researchers say people should focus on diet and exercise, limit alcohol, manage stress, get enough sleep, and more.
Christian Ruff, MD
February 11th 2025

Abelacimab Shows Potential to Shift the Standard of Care in AFib

Kyle Munz Christian Ruff, MD Dan Bloomfield, MD
Results from the AZALEA-TIMI 71 phase 2 trial showed great promise for abelacimab to transform care for high-risk patients with atrial fibrillation.
Christian Ruff, MD
February 6th 2025

Dr Ruff Explores Mitigating Surgical Bleeding in AFib With Abelacimab

Kyle Munz Christian Ruff, MD
Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.
Conceptualizing reduced cost and increased value | image credit: patpitchaya - stock.adobe.com
February 3rd 2025

Polypill Treatment: A Clinically Effective and Cost-Saving Strategy for CVD Management

Kyle Munz
A polypill for preventing cardiovascular disease has the potential to address health inequities and expand health care access for low-income populations.
FDA approval | image credit: Aquir - stock.adobe.com
January 28th 2025

FDA Expands Semaglutide Use for CV, Kidney Risks in T2D, CKD

Kyle Munz
The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes (T2D) and chronic kidney disease (CKD), addressing their cardiovascular (CV) and kidney disease risks.
Glass of sugar cubes | Image Credit: © grzejnik1981-stock.adobe.com
January 28th 2025

Curbing Sugary Beverages for Health and Economic Gains

Maggie L. Shaw
According to the CDC, frequent consumption of sugary drinks is linked to adverse health outcomes that include obesity, type 2 diabetes, heart disease, nonalcoholic liver disease, and gout.
Atrial fibrillation | image credit: Uladzlislau - stock.adobe.com
January 22nd 2025

Abelacimab, a “Game Changer” for High-Risk Patients With AFib: Dr Ruff and Dr Bloomfield Elaborate on Latest Data From AZALEA-TIMI 71 Trial

Kyle Munz Christian Ruff, MD Dan Bloomfield, MD
Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients with atrial fibrillation (AFib).
Breast cancer awareness graphic | image credit: ST.art - stock.adobe.com
January 15th 2025

Breast Cancer Stage May Influence Risk of Prevalent CVD

Kyle Munz
Patient outcomes appeared to be more heavily driven by breast cancer stage than delays in diagnosis, researchers found.
12345678
...
24>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo